Ribociclib succinate hydrate is primarily used in the treatment of certain types of breast cancer. It is specifically indicated for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, often in combination with other therapies such as aromatase inhibitors. The compound works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which play a crucial role in cell division and proliferation. By blocking these kinases, it helps to slow down or stop the growth of cancer cells. This targeted approach makes it a valuable option in personalized cancer treatment regimens, improving progression-free survival for patients. It is typically administered orally, offering convenience and flexibility in its use. Ongoing research is exploring its potential in other cancer types and combination therapies.